Ocular Therapeutix, Inc (OCUL) stock
OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)
Close on Nov 17, 2026Market cap $1.32BP/E –Yield –
Ocular Therapeutix enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Ocular Therapeutix's enterprise value was $936.62M on Nov 11, 2026, against $1.85B a year earlier. Over the last 5 years it ranged from $119.90M to $1.85B, with a median of $831.09M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $936.62M | -49.4% |
| 2025 | Dec 31, 2025 | $1.85B | +89.1% |
| 2024 | Dec 31, 2024 | $978.43M | +216.9% |
| 2023 | Dec 29, 2023 | $308.75M | +155.9% |
| 2022 | Dec 30, 2022 | $120.64M | -68.2% |
| 2021 | Dec 31, 2021 | $379.61M | -69.7% |
| 2020 | Dec 31, 2020 | $1.25B | +739.0% |
| 2019 | Dec 31, 2019 | $149.45M | +32.8% |
| 2018 | Dec 31, 2018 | $112.50M | +20.3% |
| 2017 | Dec 29, 2017 | $93.54M | -35.2% |
| 2016 | Dec 30, 2016 | $144.28M | +13.3% |
| 2015 | Dec 31, 2015 | $127.33M | -70.8% |
| 2014 | Dec 31, 2014 | $435.39M | – |
See a number that looks wrong?